An official website of the United States government
Erratum: Vol. 73, No. 21
Weekly / July 11, 2024 / 73(27);612
The report “Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024” contained several errors.
On page 489, the sixth sentence in the Abstract should have read, “Reporting rates of GBS after RSV vaccination in VAERS (4.4 and 1.8 reports per million doses of Abrysvo and Arexvy vaccine administered, respectively) were higher than estimated expected background rates in a vaccinated population.”
On page 489, the fourth complete sentence in the second column should have read, “Estimated VAERS GBS reporting rates after RSV vaccination were 4.4 and 1.8 reports per million administered doses of Pfizer and GSK vaccines, respectively.”
On page 490, the final sentence beginning in the second column should have read, “During May 3, 2023–April 14, 2024, VAERS received and processed 3,200 reports of adverse events among persons aged ≥60 years who reported receiving an RSV vaccine (Table 3),††† including 2,193 (68.5%) for GSK vaccine, 919 (28.7%) for Pfizer, and 88 (2.8%) for which the vaccine manufacturer was unknown.”
On page 492, the first complete sentence should have read, “Among the 28 reports of GBS after vaccination that met case definition, 13 (46.4%) were after GSK vaccine (1.8 reports per 1 million doses administered), and 15 (53.6%) were after Pfizer vaccine (4.4 reports per 1 million doses administered).”
On page 492, the third sentence in the second column should have read, “Using VAERS data, estimated GBS reporting rates after RSV vaccination among persons aged ≥60 years were 4.4 and 1.8 reports per million doses of Pfizer and GSK vaccine administered, respectively.”
On page 493, in Table 3, the total participants for GSK should have read 2,193, and the total participants for Pfizer should have read 919. Under “Events among serious reports,” the GSK number and percentage should have read 167 (7.6), and the Pfizer number and percentage should have read 98 (10.7). Under “Guillain-Barré syndrome,” the GSK number should have read 18, and the Pfizer number should have read 19.
On page 494, in the Summary, the sentence under “What is added by this report?” should have read, “Findings are consistent with those from trials; reports of GBS (4.4 and 1.8 reports per million doses of Abrysvo and Arexvy vaccine administered, respectively) were more common than expected background rates.
Suggested citation for this article: Erratum: Vol. 73, No. 21. MMWR Morb Mortal Wkly Rep 2024;73:612. DOI: http://dx.doi.org/10.15585/mmwr.mm7327a4.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.